Skip Navigation
National Cancer Institute U.S. National Institutes of Health National Cancer Institute
Chromosomes
  • Tools
  • Genetic and Physical SNP Maps
  • SNP500Cancer

Association List

[Full Text]
Displaying Investigations 1 to 53 of 53 found
From 10 References


Babiceanu et al 2016, Nucleic Acids Res
  Nonneoplastic hematologic disorder/lesion Lymph node
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Thyroid
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Gallbladder/Biliary system
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Testis
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Bladder
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Skin
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic hematologic disorder/lesion
HACL1/COLQ
t(3;3)(p25;p25)
  Nonneoplastic epithelial disorder/lesion Uterus, corpus
HACL1/COLQ
t(3;3)(p25;p25)

Francis et al 2012, PLoS One
  Chronic myeloid leukemia, t(9;22)
BRK1/VHL
t(3;3)(p25;p25)

Giacomini et al 2013, PLoS Genet
  Adenocarcinoma Pancreas
ATG7/RAF1
t(3;3)(p25;p25)

Gu et al 2016, Nat Commun
  Acute lymphoblastic leukemia/lymphoblastic lymphoma
RAF1/TMEM40
t(3;3)(p25;p25)
B-Lineage

Hu et al 2018, Nucleic Acids Res
  Germ cell tumor, NOS Testis
CRELD1/FANCD2OS
t(3;3)(p25;p25)
  Adenocarcinoma Prostate
EAF1/CAND2
t(3;3)(p25;p25)
  Mesenchymal tumor, NOS Unknown site
FGD5/SLC6A6
t(3;3)(p25;p25)
  Adenocarcinoma Uterus, corpus
GHRL/SEC13
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
HRH1/TSEN2
t(3;3)(p25;p25)
  Malignant melanoma Skin
IL17RC/TTLL3
t(3;3)(p25;p25)
  Adenocarcinoma Oesophagus
IRAK2/BRK1
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
MKRN2/PPARG
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
RAF1/IQSEC1
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
RPUSD3/EMC3
t(3;3)(p25;p25)
  Adenocarcinoma Breast
SETD5/LMCD1
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
SETD5/RAD18
t(3;3)(p25;p25)
  Adenocarcinoma Uterus, corpus
SRGAP3/LHFPL4
t(3;3)(p25;p25)
  Squamous cell carcinoma Uterus, cervix
TAMM41/ATG7
t(3;3)(p25;p25)
  Malignant melanoma Skin
TATDN2/IRAK2
t(3;3)(p25;p25)
  Adenocarcinoma Oesophagus
TATDN2/FANCD2
t(3;3)(p25;p25)
  Mesenchymal tumor, NOS Unknown site
TSEN2/ATG7
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
TSEN2/SYN2
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
VGLL4/TMEM40
t(3;3)(p25;p25)
  Adenocarcinoma Stomach
VGLL4/IQSEC1
t(3;3)(p25;p25)
  Astrocytoma, grade I-II Brain
VHL/FANCD2OS
t(3;3)(p25;p25)

Imielinski et al 2012, Cell
  Adenocarcinoma Lung
TTLL3/MTMR14
t(3;3)(p25;p25)

Phillips et al 2016, Acta Neuropathol
  Neuroglial neoplasm, special type Brain
ATG7/RAF1
t(3;3)(p25;p25)

Pintarelli et al 2016, Oncotarget
  Nonneoplastic epithelial disorder/lesion Lung
ARPC4/TTLL3
t(3;3)(p25;p25)

Yoshihara et al 2015, Oncogene
  Adenocarcinoma Ovary
SH3BP5/METTL6
t(3;3)(p25;p25)
  Adenocarcinoma Lung
RAF1/XPC
t(3;3)(p25;p25)
  Adenocarcinoma Lung
VGLL4/TAMM41
t(3;3)(p25;p25)
  Adenocarcinoma Lung
NUP210/FBLN2
t(3;3)(p25;p25)
  Adenocarcinoma Kidney
TATDN2/SETD5
t(3;3)(p25;p25)
  Adenocarcinoma Kidney
RAF1/TMEM40
t(3;3)(p25;p25)
  Astrocytoma, grade I-II Brain
ATG7/PPARG
t(3;3)(p25;p25)
  Squamous cell carcinoma Oral cavity
SRGAP3/ATP2B2
t(3;3)(p25;p25)
  Squamous cell carcinoma Oral cavity
IRAK2/SRGAP3
t(3;3)(p25;p25)
  Adenocarcinoma Breast
SETD5/ATG7
t(3;3)(p25;p25)
  Adenocarcinoma Breast
FANCD2/MTMR14
t(3;3)(p25;p25)
  Adenocarcinoma Breast
VGLL4/SH3BP5
t(3;3)(p25;p25)
  Adenocarcinoma Breast
NR2C2/COLQ
t(3;3)(p25;p25)
  Adenocarcinoma Breast
NR2C2/FGD5
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
TSEN2/PPARG
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
PPARG/SYN2
t(3;3)(p25;p25)
  Transitional cell carcinoma Bladder
IQSEC1/WNT7A
t(3;3)(p25;p25)

Zheng et al 2016, Cancer Cell
  Adenocarcinoma Adrenal
BRK1/FANCD2
t(3;3)(p25;p25)